# A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL

Source: https://onco.cc/trials/nct06375733/  
OnCo record `nct06375733` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Zanubrutinib in diffuse large B-cell lymphoma, run by Genfleet Therapeutics (Shanghai) Inc., now recruiting.

## Summary

A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL is a phase 1/2 interventional study registered as NCT06375733 by Genfleet Therapeutics (Shanghai) Inc., with 51 participants planned, started 2024-03-20 and due to reach its primary completion in 2026-12-31. Interventions recorded: GFH009 and Zanubrutinib.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06375733
- Phase: 1/2
- Setting: A Phase Ib/II, Multicenter, Open-label, Single-arm Study to Assess the Safety and Efficacy of GFH009 in Combination With Zanubrutinib in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
- Sponsor: Genfleet Therapeutics (Shanghai) Inc.
- Enrolled: 51

## Sources

- ClinicalTrials.gov NCT06375733: https://clinicaltrials.gov/study/NCT06375733

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/)
- drugs: [Zanubrutinib](https://onco.cc/drugs/zanubrutinib/)

---
JSON: https://onco.cc/api/v1/entities/nct06375733.json